Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Wearable ECG patch could unlock hidden heart risks

NCT ID NCT07775976

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study is testing whether a wearable ECG patch, combined with AI analysis, can help doctors identify a wide range of heart conditions and risks from a single recording. The Cor360 system looks at many aspects of heart health at once, such as heart failure, rhythm problems, and sleep apnea, to create a detailed report for clinicians. Researchers will ask doctors if these reports are useful and whether they change how they would care for their patients. The goal is to see if this technology can provide a more complete picture of heart health than traditional monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
COR wearable ECG monitoring and AI-enabled decision-support reporting
What this could lead to
If successful, this could give doctors a powerful new tool to detect heart problems earlier and guide more personalized care, potentially preventing serious events like heart failure or sudden cardiac arrest.
What could go wrong
This is an observational study, so it won't prove the system improves health outcomes. The results depend on how well the AI performs in real-world settings, and there's a risk it may not be as accurate or useful as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years or older with completed or planned Cor XT or Cor MDx wearable ECG monitoring whose data are eligible for Cor360 processing. The population may include individuals with known or suspected cardiovascular or cardiopulmonary disease, symptomatic or higher-risk patients, post-acute or post-procedural populations, and healthy asymptomatic individuals, including athletes, where permitted by the applicable subprotocol. Eligible data may derive from retrospective, prospective, longitudinal, ambidirectional, streaming-telemetry, or patient-activated-event workflows across home, ambulatory, outpatient, hospital, emergency, triage, or transport settings. Licensed healthcare professionals who complete required Cor360 training and attestation participate as clinician reviewers.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - Patient/Subject * Age 18 years or older at the time of Cor XT or Cor MDx wearable ECG monitoring. * Completed or planned Cor XT or Cor MDx wearable ECG monitoring with sufficient raw data and metadata for Cor360 processing. * Availability of required study identifiers, monitoring duration, device type, and data-quality metadata. * Monitoring may occur in approved home, clinic, ambulatory, hospital/triage, emergency-care, ambulance, transport, or clinic-to-home settings as permitted by the applicable subprotocol, IRB approval, consent/authorization pathway, site workflow, and device-use controls. * For prospective participation, ability and willingness to comply with applicable consent and monitoring procedures unless an IRB-approved alternative applies. * For Subprotocol E, at least one eligible historical COR study and at least one planned prospective COR study, with authorization permitting linked historical and prospective analysis. Exclusion Criteria - Patient/Subject * Insufficient or corrupted Cor XT or Cor MDx wearable ECG data that precludes meaningful Cor360 report generation. * Missing authorization, informed consent, waiver, or data-use permission required for analysis. * Data-provenance uncertainty that prevents linkage to the correct subject or study record. * Any condition or circumstance that, in the investigator's judgment, makes study-data use inappropriate or unsafe. Inclusion Criteria - Clinician Reviewer * Active professional license in an applicable jurisdiction and practice within professional scope. * Training or clinical role relevant to cardiology, electrophysiology, internal medicine, family medicine, pulmonology, sleep medicine, emergency medicine, advanced-practice cardiology, or related care pathways. * Completion of Cor360 training and clinician attestation before report access. * Agreement to use Cor360 reports only under protocol-defined conditions and to report discrepancies or safety concerns. Exclusion Criteria - Clinician Reviewer * Inactive, restricted, or suspended clinical license. * Failure to complete required Cor360 training or attestation. * Failure to comply with confidentiality, privacy, or protocol obligations. * Investigator or Sponsor determination that continued participation is inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmias, cardiac are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peerbridge Health, Inc.

    Pasadena, California, 91107, United States

  • Peerbridge Health, Inc.

    Nashville, Tennessee, 37076, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.